We summarized our experience in transurethral seminal vesiculoscopy （TSV） for recurrent hemospermia by introducing surgical techniques, intraoperative findings, and treatment outcomes. TSV was performed in 419 patie...We summarized our experience in transurethral seminal vesiculoscopy （TSV） for recurrent hemospermia by introducing surgical techniques, intraoperative findings, and treatment outcomes. TSV was performed in 419 patients with an initial diagnosis of persistent hemospermia at Shanghai Changhai Hospital （Shanghai, China） from May 2007 to November 2015. TSV was successfully performed in 381 cases （90.9%）. Hemospermia was alleviated or disappeared in 324 （85.0%） patients by 3 months after surgery. Common intraoperative manifestations were bleeding, obstruction or stenosis, mucosal lesions, and calculus. Endoscopic presentation of the ejaculatory duct orifice and the verumontanum was categorized into four types, including 8 （1.9%）, 32 （7.6%）, 341 （81.4%）, and 38 （9.1%） cases in Types A, B, C, and D, respectively. TSV is an effective and safe procedure in the management of seminal tract disorders. This study may help other surgeons to become familiar with and improve this procedure. However, further multicentric clinical trials are warranted to validate these findings.展开更多
文摘We summarized our experience in transurethral seminal vesiculoscopy （TSV） for recurrent hemospermia by introducing surgical techniques, intraoperative findings, and treatment outcomes. TSV was performed in 419 patients with an initial diagnosis of persistent hemospermia at Shanghai Changhai Hospital （Shanghai, China） from May 2007 to November 2015. TSV was successfully performed in 381 cases （90.9%）. Hemospermia was alleviated or disappeared in 324 （85.0%） patients by 3 months after surgery. Common intraoperative manifestations were bleeding, obstruction or stenosis, mucosal lesions, and calculus. Endoscopic presentation of the ejaculatory duct orifice and the verumontanum was categorized into four types, including 8 （1.9%）, 32 （7.6%）, 341 （81.4%）, and 38 （9.1%） cases in Types A, B, C, and D, respectively. TSV is an effective and safe procedure in the management of seminal tract disorders. This study may help other surgeons to become familiar with and improve this procedure. However, further multicentric clinical trials are warranted to validate these findings.
